Close Menu

NEW YORK – Bionano Genomics reported after the close of the market on Thursday a 31 percent year-over-year decrease in its fourth quarter revenues.

The San Diego-based genome mapping firm reported $2.8 million in Q4 revenue, down from $4.0 million a year ago. Revenues consisted of $1.5 million in instrument revenue, down 50 percent from Q4 2018 and consumables revenue of $1.1 million, up 35 percent from the prior year period.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.